MIRO · Miromatrix Medical Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | $953.5K | $46.5K |
| Cost of Revenue | $500.0K | $500.0K |
| Gross Profit | $453.5K | ($453.5K) |
| R&D | $18.30M | $7.28M |
| SG&A | $8.72M | $2.11M |
| Total Operating Expenses | $30.82M | $9.81M |
| D&A | $1.11M | $170.4K |
| Operating Income | ($30.36M) | ($10.26M) |
| Interest Expense | - | - |
| Income Tax | $0 | $0 |
| Net Income | ($29.96M) | ($10.31M) |
| EPS - Basic | ($1.45) | ($4.76) |
| EPS - Diluted | ($1.45) | ($4.76) |
Balance Sheet
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Cash & Equivalents | $5.21M | $52.81M |
| Accounts Receivable | - | - |
| Inventory | - | - |
| Accounts Payable | $1.58M | $2.09M |
| Current Assets | $27.31M | $55.34M |
| Total Assets | $34.76M | $60.93M |
| Current Liabilities | $4.95M | $4.56M |
| Long-term Debt | $386.0K | $386.0K |
| Total Liabilities | $8.66M | $6.80M |
| Stockholders' Equity | $26.11M | $54.13M |
| Retained Earnings | ($104.01M) | ($74.05M) |
Cash Flow
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Operating Cash Flow | ($26.68M) | ($8.04M) |
| Investing Cash Flow | ($21.09M) | $2.88M |
| Financing Cash Flow | $168.3K | $6.36M |
| CapEx | $1.06M | $123.2K |
| Free Cash Flow | ($27.75M) | ($8.16M) |
Ratios
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Profitability | ||
| Gross margin | 47.6% | -974.6% |
| Operating margin | -3184.6% | -22047.2% |
| EBITDA margin | -3068.4% | -21681.0% |
| Net margin | -3142.2% | -22156.8% |
| Free cash flow margin | -2910.0% | -17539.0% |
| FCF / Net income | 0.93 | 0.79 |
| R&D / Revenue | 1919.7% | 15647.5% |
| SG&A / Revenue | 914.5% | 4533.0% |
| Effective tax rate | - | - |
| Return on assets | -86.2% | -16.9% |
| Return on equity | -114.8% | -19.0% |
| Return on invested capital | -90.5% | -14.9% |
| Liquidity | ||
| Current ratio | 5.52 | 12.12 |
| Quick ratio | 5.52 | 12.12 |
| Cash ratio | 1.05 | 11.57 |
| Leverage | ||
| Debt / Equity | 0.01 | 0.01 |
| Debt / Assets | 0.01 | 0.01 |
| Debt / EBITDA | - | - |
| Interest coverage | - | - |
| Equity multiplier | 1.33 | 1.13 |
| Liabilities / Assets | 0.25 | 0.11 |
| Efficiency | ||
| Asset turnover | 0.03 | 0.00 |
| Inventory turnover | - | - |
| Days sales outstanding | - | - |
| Days inventory outstanding | - | - |
| Days payable outstanding | 1157d | 1529d |
| Cash conversion cycle | - | - |
| Valuation | ||
| P / E | - | - |
| P / B | - | - |
| P / S | - | - |
| EV / EBITDA | - | - |
| Growth | ||
| Revenue growth (YoY) | 1949.2% | - |
| Revenue CAGR (3y) | - | - |
| Revenue CAGR (5y) | - | - |
| Gross profit growth (YoY) | - | - |
| Operating income growth (YoY) | -196.0% | - |
| Net income growth (YoY) | -190.6% | - |
| EPS growth (YoY) | 69.5% | - |
| EPS CAGR (3y) | - | - |
| EPS CAGR (5y) | - | - |
| FCF growth (YoY) | -240.0% | - |
| FCF CAGR (5y) | - | - |
| Book value growth (YoY) | -51.8% | - |
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-3.49
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Miromatrix Medical Inc. against the 5 most active filers in the same SIC group.